Decreased numbers of <i>dicer</i>^<i>CKO</i> P14 effector cells demonstrate an intrinsic role of Dicer during CD8 T cell expansion. by Florian M. Baumann (3119772)

Illustration of the main differences in ulna morphology between running groups, based on morphometric and microarchitecture analyses. by Andy Xavier (20141395)

Agent model of latency. by John M. Murray (150672)

Raw data. by Wei Li (7081)

“…The purpose of this study was to assess the cost-effectiveness of sugemalimab vs. placebo for consolidation treatment of stage III NSCLC from the perspective of the Chinese healthcare system.</p><p>Methods</p><p>A 3-state Markov model with a 3-week cycle length was performed to appraise the incremental cost-utility ratio (ICUR) of sugemalimab consolidation therapy based on the GEMSTONE-301 clinical trial over a 10-year time horizon. …”

Best fit and the values of the parameters. by Wei Li (7081)

“…The purpose of this study was to assess the cost-effectiveness of sugemalimab vs. placebo for consolidation treatment of stage III NSCLC from the perspective of the Chinese healthcare system.</p><p>Methods</p><p>A 3-state Markov model with a 3-week cycle length was performed to appraise the incremental cost-utility ratio (ICUR) of sugemalimab consolidation therapy based on the GEMSTONE-301 clinical trial over a 10-year time horizon. …”

Base-case analysis results without or with PAP. by Wei Li (7081)

“…The purpose of this study was to assess the cost-effectiveness of sugemalimab vs. placebo for consolidation treatment of stage III NSCLC from the perspective of the Chinese healthcare system.</p><p>Methods</p><p>A 3-state Markov model with a 3-week cycle length was performed to appraise the incremental cost-utility ratio (ICUR) of sugemalimab consolidation therapy based on the GEMSTONE-301 clinical trial over a 10-year time horizon. …”

Results of scenario analyses for cCRT population. by Wei Li (7081)

“…The purpose of this study was to assess the cost-effectiveness of sugemalimab vs. placebo for consolidation treatment of stage III NSCLC from the perspective of the Chinese healthcare system.</p><p>Methods</p><p>A 3-state Markov model with a 3-week cycle length was performed to appraise the incremental cost-utility ratio (ICUR) of sugemalimab consolidation therapy based on the GEMSTONE-301 clinical trial over a 10-year time horizon. …”

Live-cell imaging reveals multiple patterns of Tax expression in naturally-infected T-cell clones. by Saumya Ramanayake (7879091)

Results of scenario analyses for sCRT population. by Wei Li (7081)

“…The purpose of this study was to assess the cost-effectiveness of sugemalimab vs. placebo for consolidation treatment of stage III NSCLC from the perspective of the Chinese healthcare system.</p><p>Methods</p><p>A 3-state Markov model with a 3-week cycle length was performed to appraise the incremental cost-utility ratio (ICUR) of sugemalimab consolidation therapy based on the GEMSTONE-301 clinical trial over a 10-year time horizon. …”

Baseline characteristics of participants. by Hyungjong Park (10147327)

“…In the multivariable Cox regression analysis, eGFR > 120 mL/min ∙ 1.73 m² was associated with a decreased risk of dyslipidemia (HR: 0.35; 95% CI [0.34–0.36]). …”

Determination of SCFA content in fecal stool and intestinal metabolites of rats in each group. by Shudan Liu (7049483)

S1 Data - by Kadio Jean-Jacques Olivier Kadio (15503159)

“…The LTFU rate was 54.5 per 1000 person-months (95% CI 53.6–55.4), with the peak hazards of LTFU occurring after the first visit and decreasing steadily over time. In an adjusted analysis, the hazards of LTFU were higher among men compared to women (aHR = 1.10; 95%CI 1.08–1.12), being aged 13–25 years old versus older patients (aHR = 1.07; 95%CI = 1.03–1.13), and among those initating ART in smaller health facilities (aHR = 1.52; 95%CI 1.45–1.60). …”

Participant characteristics. by Kadio Jean-Jacques Olivier Kadio (15503159)

“…The LTFU rate was 54.5 per 1000 person-months (95% CI 53.6–55.4), with the peak hazards of LTFU occurring after the first visit and decreasing steadily over time. In an adjusted analysis, the hazards of LTFU were higher among men compared to women (aHR = 1.10; 95%CI 1.08–1.12), being aged 13–25 years old versus older patients (aHR = 1.07; 95%CI = 1.03–1.13), and among those initating ART in smaller health facilities (aHR = 1.52; 95%CI 1.45–1.60). …”

Expression pattern of microRNA clusters within the <i>Ftx</i> transcript and their correlation with key clinical features. by Qi Zhao (124612)

Reservoir dynamics. by John M. Murray (150672)

A Comparison of Pediatric Prehospital Opioid Encounters and Social Vulnerability by Stephen Sandelich (19991783)

“…Lower socioeconomic status (SES) areas (higher SVI scores) exhibited a decreased rate of opioid-related activations compared to lower SVI-scored areas but an increased frequency of naloxone administration. …”

Figure S1 - Potent PPARα Activator Derived from Tomato Juice, 13-oxo-9,11-Octadecadienoic Acid, Decreases Plasma and Hepatic Triglyceride in Obese Diabetic Mice by Young-il Kim (184302)

Selected headwater subcatchment for model calibration in the five river basins (refer to Fig 2 for gauge location). by Fazlul Karim (7225826)

Exercise protocols. by Andy Xavier (20141395)

Fig 4 - by Kadio Jean-Jacques Olivier Kadio (15503159)